-

The Phadia 2500+ Instrument Family Now Available in the U.S. for Autoimmune Testing

New offering from Thermo Fisher Scientific expands instrument capabilities beyond allergy diagnostics

PORTAGE, Mich.--(BUSINESS WIRE)--The new Phadia 2500+ series of instruments is now available for autoimmune testing in the U.S. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.

This expanded capability of the Phadia 2500+ series of instruments allows for instrument consolidation and enables additional automation for EliA autoimmune diagnostics, aiding in the diagnosis of autoimmune diseases including Connective Tissue Disease (CTD), Antiphospholipid Syndrome (APS), Celiac Disease, Rheumatoid Arthritis, Autoimmune Liver Disease and Autoimmune Thyroid Disease.

“Increasingly, laboratorians are being asked to further streamline their workflows and become more efficient,” said Michele Zwickl, vice president, commercial operations, U.S., ImmunoDiagnostics, Thermo Fisher. “With the launch of the Phadia 2500+ series, we now offer scalable, high-capacity allergy and autoimmune diagnostics instrumentation that can help large labs be more productive with existing resources.”

The Phadia 2500+ series of instruments is capable of serving laboratories with demands exceeding 10,000 test results every week and maximizes productivity by providing options to run EliA and ImmunoCAP testing in parallel on a single instrument. Its high throughput automation allows laboratories to process up to 480 ImmunoCAP results per hour and up to 300 EliA autoimmunity results per hour.

The series of instruments includes the Phadia 2500 (ImmunoCAP analyzer), Phadia 2500EE (EliA analyzer) and Phadia 2500E (ImmunoCAP and EliA analyzer). For more information on Phadia 2500+ series of instruments, please visit: https://www.thermofisher.com/phadia/us/en/our-solutions/phadia-laboratory-systems/phadia-2500.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Angela Christoforos
508-801-2391
achristoforos@greenough.biz

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Angela Christoforos
508-801-2391
achristoforos@greenough.biz

More News From Thermo Fisher

Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026

MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization, reduce friction, and maintain momentum. The company will showcase these new and expanded capabilities at CPHI Milan 2026, Oct. 6-8. Among the new offerings is OSD Express, a defined solution designed to increase predictability...

Thermo Fisher Scientific Proteomics Technologies Enable Discovery of More Than 2,500 New Biological Associations in PRECISE-SG100K Study

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its strategic collaboration with Precision Health Research, Singapore (PRECISE) and Nanyang Technological University, Singapore (NTU Singapore) has led to the discovery of more than 2,500 previously unreported genetic-protein associations. By combining Thermo Fisher’s complementary proteomics technologies with PRECISE-SG100K's large-scale health and genomic data, researchers...

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2026 before the market opens on Wednesday, October 21, 2026, and will hold a conference call on the same day at 7:00 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. The call will be webcast live on the “Investors” section of our website, www.thermof...
Back to Newsroom